Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes (Q37360316)

19 August 2017

1 reference

title

Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes (English)

1 reference

19 August 2017

0 references

1 reference

Daniel J Drucker

1 reference

19 August 2017

Safina Ali

1 reference

19 August 2017

publication date

30 December 2008

1 reference

American Journal of Physiology - Endocrinology and Metabolism

19 August 2017

published in

1 reference

19 August 2017

volume

296

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

E415-21

1 reference

Glucagon suppression of ghrelin secretion is exerted at hypothalamus-pituitary level

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Underestimation of gluconeogenesis by the [U-(13)C(6)]glucose method: effect of lack of isotope equilibrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Insulin as a physiological modulator of glucagon secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Effects of Exogenous Glucagon on Lipids in Lipoproteins and Liver of Lactating Dairy Cows

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glucagon increases contractility in ventricle but not in atrium of the rat heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Identification of glucagon receptors in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Effect of intracerebroventricularly infused glucagon on feeding behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Expression cloning and signaling properties of the rat glucagon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glucagon and regulation of glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Discovery of potent, orally active benzimidazole glucagon receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

New beta-alanine derivatives are orally available glucagon receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type 2 diabetes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

The glucagon receptor is required for the adaptive metabolic response to fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glucagon-Sensitive Adenylate Cyclase in Human Renal Medulla

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glycemic control in mice with targeted disruption of the glucagon receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glucagon effects on the human small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Glucagon receptor signaling is essential for control of murine hepatocyte survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

21 January 2018

Glucagon and the colon

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Lesion of vagal afferent terminals impairs glucagon-induced suppression of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90887.2008

10.1152/AJPENDO.90887.2008

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference